GW Pharmaceuticals to Present at Upcoming Investor Conferences
October 31 2019 - 7:00AM
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich
Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the
world leader in the science, development, and commercialization of
cannabinoid prescription medicines, today announced that Stephen
Schultz, GW’s Vice President of Investor Relations, will present at
two upcoming conferences:
- the Guggenheim Healthcare Talks
Idea Forum, Neuro/Immunology Day, on Monday, November 18th, 2019 at
10:30 a.m. EST
- the Stifel 2019 Healthcare
Conference on Wednesday, November 20, 2019 at 1:15 p.m. EST
A live audio webcast of the presentations will
be available through GW’s corporate website at www.gwpharm.com on
the Investors section under Events & Presentations. A replay
will be available for each soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW’s lead
product, EPIDIOLEX (cannabidiol) oral solution is commercialized in
the U.S. by its U.S. subsidiary Greenwich Biosciences for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older. This
product has received approval in Europe under the tradename
EPIDYOLEX and is initially being commercialized in the 5 EU major
markets. The Company continues to evaluate EPIDIOLEX in additional
rare conditions including Tuberous Sclerosis Complex (TSC) and Rett
syndrome. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex® (nabiximols), which is
approved for the treatment of spasticity due to multiple sclerosis
in numerous countries outside the United States and for which the
Company is now advancing a late stage program in order to seek FDA
approval. The Company has a deep pipeline of additional cannabinoid
product candidates which includes compounds in Phase 1 and 2 trials
for epilepsy, autism, glioblastoma, and schizophrenia. For further
information, please visit
www.gwpharm.com.Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024